Local Radiotherapy for Residual Tumor Lesions During the First-line

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05094804` - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents	Phase 1/Phase 2
Recruiting	`NCT04258137` - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study	N/A
Completed	`NCT01945021` - Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC	Phase 2
Recruiting	`NCT04487457` - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Terminated	`NCT04022876` - A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)	Phase 1
Recruiting	`NCT05532696` - Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients	Phase 1/Phase 2
Active, not recruiting	`NCT04311034` - A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer	Phase 1/Phase 2
Recruiting	`NCT03257722` - Pembrolizumab + Idelalisib for Lung Cancer Study	Phase 1/Phase 2
Active, not recruiting	`NCT03177291` - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC	Phase 1
Completed	`NCT00349089` - Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy	Phase 2
Active, not recruiting	`NCT05116891` - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04571632` - Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors	Phase 2
Not yet recruiting	`NCT04650490` - SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer	Phase 2
Withdrawn	`NCT03982134` - PDR001 + Panobinostat for Melanoma and NSCLC	Phase 1
Withdrawn	`NCT03574649` - QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer	Phase 2
Withdrawn	`NCT02844140` - DE-CT in Lung Cancer Proton Therapy	N/A
Completed	`NCT03780010` - Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC	Phase 1
Terminated	`NCT02628535` - Safety Study of MGD009 in B7-H3-expressing Tumors	Phase 1
Active, not recruiting	`NCT02136355` - A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early Non-Small Cell Lung Cancer	N/A
Withdrawn	`NCT01913067` - Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC	Phase 2

NCT number	NCT05205226
Study type	Observational
Source	Hunan Province Tumor Hospital
Contact
Status	Completed
Phase
Start date	January 2, 2018
Completion date	January 2, 2022

Local Radiotherapy for Residual Tumor Lesions During the First-line Treatment

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms